Clearmind Medicine treats 20 participants in Phase I/IIa trial of CMND-100 for alcohol use disorder

Clearmind Medicine has reached a milestone by dosing 20 participants in its ongoing Phase I/IIa clinical trial of CMND-100, a non-hallucinogenic treatment for moderate to severe Alcohol Use Disorder (AUD). The trial, conducted at multiple international sites including Israel and the US, continues to show strong safety and tolerability results, with no serious adverse events reported so far. The company is advancing the dose-escalation phase, aiming to develop a new therapeutic option for AUD patients. This progress supports Clearmind's goal to bring innovative, neuroplastogen-derived treatments to market.